ES2073180T3 - Vacuna adecuada para combatir la bacteria bordetella pertussis. - Google Patents

Vacuna adecuada para combatir la bacteria bordetella pertussis.

Info

Publication number
ES2073180T3
ES2073180T3 ES91919318T ES91919318T ES2073180T3 ES 2073180 T3 ES2073180 T3 ES 2073180T3 ES 91919318 T ES91919318 T ES 91919318T ES 91919318 T ES91919318 T ES 91919318T ES 2073180 T3 ES2073180 T3 ES 2073180T3
Authority
ES
Spain
Prior art keywords
omps
bordetella pertussis
formulation
suitable vaccine
vesicula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91919318T
Other languages
English (en)
Inventor
Hendrik-Jan Hamstra
Jan Teunis Poolman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nederlanden Staat
Nederlanden Welzijn Volksgezondheid en Cultuur Minister van
Original Assignee
Nederlanden Staat
Nederlanden Welzijn Volksgezondheid en Cultuur Minister van
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nederlanden Staat, Nederlanden Welzijn Volksgezondheid en Cultuur Minister van filed Critical Nederlanden Staat
Application granted granted Critical
Publication of ES2073180T3 publication Critical patent/ES2073180T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/235—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bordetella (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

LA INVENCION SE REFIERE A VACUNAS, QUE SON ADECUADAS PARA COMBATIR LA "BORDETELLA PERTUSSIS", EL ORGANISMO CAUSANTE DE LA TOS FERINA. MAS PARTICULARMENTE, LAS VACUNAS COMPRENDEN, COMO COMPONENTE ACTIVO UNA O MAS PROTEINAS DE LA MEMBRANA EXTERIOR (OMPS) DERIVADA DE LA "BORDETELLA PERTUSSIS" O DE MICROORGANISMOS GENETICAMENTE MANIPULADOS QUE PRODUCEN DICHAS OMPS. PREFERIBLEMENTE LAS OMPS QUE TIENEN UN PESO MOLECULAR ENTRE 32 KDA Y 92 KDA (TANTO SEPARADAS COMO EN COMBINACION) SE APLICAN COMO COMPONENTE ACTIVO. DE ACUERDO CON UNA CONFORMACION DE LA INVENCION LAS OMPS EN CUESTION ESTAN PRESENTES EN LA FORMULACION DE LA VESICULA DE LA MEMBRANA EXTERIOR (OMV) O EN LA FORMULACION DE LA VESICULA ARTIFICIAL SIMILAR A LA FORMULACION DE LA PROTEINA-DETERGENTE.
ES91919318T 1990-09-25 1991-09-25 Vacuna adecuada para combatir la bacteria bordetella pertussis. Expired - Lifetime ES2073180T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NL9002092A NL9002092A (nl) 1990-09-25 1990-09-25 Vaccin, geschikt voor de bestrijding van bordetella pertussis.

Publications (1)

Publication Number Publication Date
ES2073180T3 true ES2073180T3 (es) 1995-08-01

Family

ID=19857724

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91919318T Expired - Lifetime ES2073180T3 (es) 1990-09-25 1991-09-25 Vacuna adecuada para combatir la bacteria bordetella pertussis.

Country Status (8)

Country Link
EP (1) EP0550683B1 (es)
AT (1) ATE121423T1 (es)
CA (1) CA2092420C (es)
DE (1) DE69109126T2 (es)
DK (1) DK0550683T3 (es)
ES (1) ES2073180T3 (es)
NL (1) NL9002092A (es)
WO (1) WO1992005194A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5156958A (en) * 1990-09-21 1992-10-20 American Cyanamid Company Gene encoding a 30 kilodalton outer membrane protein of bordetella pertussis and method of recombinant production of said protein
US20020028215A1 (en) 1999-08-09 2002-03-07 Jagath L. Kadurugamuwa Novel vaccines and pharmaceutical compositions using membrane vesicles of microorganisms, and methods for preparing same
AU707131B2 (en) * 1995-08-04 1999-07-01 University Of Guelph Novel vaccines and pharmaceutical compositions using membrane vesicles of microorganisms, and methods for preparing same
FR2754543B1 (fr) * 1996-10-11 1998-12-31 Pasteur Institut Souche de bordetella deficiente dans la production de toxine et exprimant une proteine hydride, liposomes comprenant de la fha et leurs utilisations comme vaccins, et utilisation de la fha pour stimuler les reponses immunitaires
FR2805163A1 (fr) * 2000-02-21 2001-08-24 Pf Medicament Utilisation d'un detergent de type zwittergent pour la preparation d'une composition pharmaceutique destinee a etre administree par voie nasale
GB0416120D0 (en) 2004-07-19 2004-08-18 Health Prot Agency Stable compositions containing OMV's

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5432690A (en) * 1989-03-31 1990-11-05 Washington University Bordetella vaccines
GB9007657D0 (en) * 1990-04-04 1990-05-30 Connaught Lab Purification of a pertussis outer membrane protein(omp69)

Also Published As

Publication number Publication date
CA2092420C (en) 1999-11-23
DK0550683T3 (da) 1995-09-04
CA2092420A1 (en) 1992-03-26
EP0550683B1 (en) 1995-04-19
WO1992005194A1 (en) 1992-04-02
DE69109126T2 (de) 1995-09-21
DE69109126D1 (de) 1995-05-24
EP0550683A1 (en) 1993-07-14
ATE121423T1 (de) 1995-05-15
NL9002092A (nl) 1992-04-16

Similar Documents

Publication Publication Date Title
CY1108875T1 (el) Βλεννοπροσφυτικα σκευασματα που περιεχουν ξυλογλυκανη και ειναι χρησιμα σε ιατρικες συσκευες και σε φαρμακευτικα σκευασματα
Cooksey Rehabilitation in vestibular injuries
CY1119951T1 (el) Συνθεσεις για αυξηση δραστηριοτητας τελομερασης και αγωγη λοιμωξης hiv
ES2565991T3 (es) Composición terapéutica y uso
CY1114243T1 (el) Συνθεσεις εμβολιου κατα της ναϊσσερια, που περιεχουν εναν συνδυασμο αντιγονων
CY1106419T1 (el) Συστημα μετατροπης φακων για τηλεδιοπτρικες ή διαθλαστικες διαταξεις
NO20111324A1 (no) Rekombinant MVA-virus
CY1108749T1 (el) Εμβολιασμος σε μια δοση me ι mycoplasma hyopneumoniae /ι
MXPA05012827A (es) Composiciones y metodo para el tratamiento de infecciones en ganado vacuno y porcino.
ECSP055725A (es) Formulaciones nutricionales que contienen sustancias simbióticas
BR0212898A (pt) Método de tratamento de infecções do ouvido médio
CY1110727T1 (el) Παρασκευασματα θετικων κατα gram βακτηριων για τη θεραπεια ασθενειων που περιλαμβανουν μια ανοσολογικη δυσρυθμιση
WO2004004757A8 (en) Treatment for eye disorder
AR009089A1 (es) Composiciones para el cuidado del color que comprenden un agente fijador de colorante y un polimero y un metodo para proporcionar cuidado de color
ES2073180T3 (es) Vacuna adecuada para combatir la bacteria bordetella pertussis.
ES2094907T3 (es) Secuencias de adn que codifican para caracteristicas de virulencia de -s(streptococcus suis) y partes del mismo, polipeptidos y anticuerpos derivados de este y su uso para la diagnosis y la proteccion contra la infeccion por -s(s. suis) en mamiferos, incluyendo el ser humano.
AR039982A1 (es) Composicion vacunal contra las alergias, metodo para su obtencion y empleo en el tratamiento de las mismas
Petrosyan et al. Bacterial melanin ameliorates symptoms of experimental autoimmune encephalomyelitis in rats
NO980300L (no) Nye höymolekylære humane MP52 proteiner
BR9814958B1 (pt) Proteína de cimento de tecido, composição farmacêutica, uso da proteína de cimento de tecido, vacina, processos para produção de vacina, para ligação de tecido de animal e para preparação de uma protéina de cimento de tecido
AR009650A1 (es) Mycoplasma synoviae atenuado vivo, su uso, un cultivo microbiologico que lo comprende, una vacuna bacteriana atenuada viva para la proteccion de las aves de corral contra la infeccion por mycoplasma synoviae y un metodo para preparar dicha vacuna.
AR042237A1 (es) Obtencion de estructuras cocleares, composiciones vacunales, adyuvantes y sus intermediarios
ES2104695T3 (es) Induccion de proteccion contra una infeccion virica.
AR046937A1 (es) Proteina nmb0928 y su uso en formulaciones farmaceuticas
AR046921A1 (es) Metodo para la incorporacion de antigenos en vesiculas de membrana externa de bacterias y formulaciones resultantes

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 550683

Country of ref document: ES